A5077076136- Hidradenitis Suppurativa and Treatments
- Psoriasis: Treatment and Pathogenesis
- Colorectal and Anal Carcinomas
- Dermatology and Skin Diseases
- Immunotherapy and Immune Responses
- Microscopic Colitis
- T-cell and B-cell Immunology
- Chemotherapy-related skin toxicity
- Anorectal Disease Treatments and Outcomes
- Asthma and respiratory diseases
- Cytokine Signaling Pathways and Interactions
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders
- Immune Cell Function and Interaction
- Inflammasome and immune disorders
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Oral Health Pathology and Treatment
- Urticaria and Related Conditions
- Immune cells in cancer
- Immune Response and Inflammation
- IL-33, ST2, and ILC Pathways
- Nonmelanoma Skin Cancer Studies
- Allergic Rhinitis and Sensitization
- melanin and skin pigmentation
Hidradenitis Suppurativa Foundation
2025
Rockefeller University
2015-2024
Albert Einstein College of Medicine
2015-2018
Montefiore Medical Center
2015-2018
Probity Medical Research
2005
Prince of Wales Hospital
1999-2000
Royal Prince Alfred Hospital
1997-2000
Calvary Mater Newcastle Hospital
2000
Centenary Institute
1997-2000
The University of Sydney
1997-2000
Background Psoriasis vulgaris is an inflammatory skin disease mediated by Th1 and Th17 cytokines, yet the relative contribution of interferon (IFN)‐γ, interleukin (IL)‐17 IL‐22 on pathogenesis still unknown. Objectives In this study, we sought to identify cytokines produced skin‐resident T cells in normal skin, localize receptors for these examine how alter gene expression profiles bearing cognate receptors. Methods We used intracellular cytokine staining flow cytometry evaluate cell...
Biological agents have dramatically improved treatment options for patients with severe psoriasis. Etanercept (tumor necrosis factor [TNF] receptor-immunoglobulin fusion protein) is an effective many psoriasis patients, and blockade of TNF considered to be its primary action. However, in this clinical trial, we show that etanercept has early inhibitory effects on a newly appreciated type T cells: helper 17 (Th17) cells. reduced the inflammatory dendritic cell products drive Th17...
We find that CD11c(+) cells with many markers of dendritic (DCs) are a major cell type in the skin lesions psoriasis. These cells, which evident both epidermis and dermis, sites for expression two mediators inflammation, inducible nitric oxide synthase (iNOS) TNF-alpha diseased skin. express HLA-DR, CD40, CD86, lack Langerin CD14 Langerhans monocytes, respectively, to significant extent DC maturation DC-LAMP CD83. Treatment psoriasis efalizumab (anti-CD11a, Raptiva) strongly reduces...
Abstract The mechanisms of action marketed TNF-blocking drugs in lesional tissues are still incompletely understood. Because psoriasis plaques accessible to repeat biopsy, the effect TNF/lymphotoxin blockade with etanercept (soluble TNFR) was studied ten patients treated for 6 months. Histological response, inflammatory gene expression, and cellular infiltration were evaluated. There a rapid complete reduction IL-1 IL-8 (immediate/early genes), followed by progressive reductions many other...
The classical Th1/Th2 paradigm previously defining atopic dermatitis (AD) and psoriasis has recently been challenged with the discovery of Th17 T cells that synthesize IL-17 IL-22. Although it is becoming evident many Th1 diseases including have a strong signal, importance in AD still unclear. We examined compared skin biopsies from patients by gene microarray, RT-PCR, immunohistochemistry, immunofluorescence. found reduced genomic expression IL-23, IL-17, IFN-gamma psoriasis. To define...
We used a panel of monoclonal antibodies to characterize DCs in the dermis normal human skin. Staining for CD11c integrin, which is abundant on many kinds DCs, revealed cells upper dermis. These were positive blood DC antigen–1 (BDCA-1; also known as CD1c), HLA-DR, and CD45, markers that are expressed by circulating myeloid DCs. A small subset CD11c+ dermal DEC-205/CD205 DC-lysosomal–associated membrane glycoprotein/CD208 (DC-LAMP/CD208), suggesting some differentiation or maturation. When...
Psoriasis vulgaris, a skin disease that is considered to be the result of type 1 autoimmune response, provides an opportunity for studying changes occur in target-diseased tissue during innovative immunotherapies. To gain more comprehensive picture response approved biological therapy, we studied alfacept, which CD2 binding fusion protein. We examined T cells, dendritic cells (DCs), and expression number inflammatory genes. In 22 patients, 55% demonstrated clear histological remission...